Does Cardizem (Diltiazem) Have Measurable Serum Levels?
Yes, diltiazem has measurable serum levels, and therapeutic plasma concentrations appear to be in the range of 50 to 200 ng/mL 1.
Clinical Monitoring and Therapeutic Range
Diltiazem plasma levels can be measured and monitored, though this is not routinely done in clinical practice. The FDA label for Cardizem specifies that minimum therapeutic plasma diltiazem concentrations appear to be in the range of 50 to 200 ng/mL 1.
Pharmacokinetic Properties
The drug demonstrates several important pharmacokinetic characteristics:
- Plasma protein binding: 70% to 80% bound to plasma proteins 1
- Elimination half-life: Approximately 3.0 to 4.5 hours after single or multiple oral doses 1
- Extended-release formulations: Half-life increases to 5 to 8 hours with CARDIZEM CD capsules 1
- Bioavailability: About 40% due to extensive first-pass metabolism 1
Active Metabolites
Diltiazem has measurable active metabolites that also appear in plasma:
- Desacetyldiltiazem (DAD): Present at 10% to 20% of parent drug levels and is 25% to 50% as potent as a coronary vasodilator 1
- N-desmethyldiltiazem (MA): Also measurable in plasma 1
Research confirms these metabolites typically represent less than 15% and 10% of diltiazem plasma concentrations, respectively 2.
Clinical Relevance of Serum Levels
Pharmacodynamic Correlation
Studies demonstrate a strong relationship between plasma diltiazem concentration and clinical effect. In patients with atrial fibrillation or flutter, research using a sigmoidal Emax pharmacodynamic model showed:
- Mean plasma concentrations of 79 ng/mL, 172 ng/mL, and 294 ng/mL are required to produce 20%, 30%, and 40% reductions in heart rate, respectively 2
- Strong correlation (r² = 0.78) between plasma concentration and percent heart rate reduction 2
Non-Linear Pharmacokinetics
Important caveat: Diltiazem exhibits dose-dependent, non-linear pharmacokinetics 1, 3. As doses increase, there is:
- Departure from linearity with dose escalation
- Apparent dose-dependent decrease in systemic clearance 2
- Disproportionate increases in area under the curve (AUC) with higher doses 3
For example, increasing the dose from 240 mg to 360 mg results in only a 1.6-fold increase in AUC, not the expected 1.5-fold increase 1.
When Serum Level Monitoring Matters
While routine therapeutic drug monitoring of diltiazem is not standard practice, serum levels become relevant in specific situations:
Drug Interactions Requiring Monitoring
The guidelines specifically recommend monitoring when diltiazem interacts with digoxin, as conflicting results exist regarding digoxin level changes. Digoxin levels should be monitored when initiating, adjusting, and discontinuing diltiazem therapy to avoid over- or under-digitalization 1.
Hepatic and Renal Impairment
Serum levels may be particularly relevant in:
- Cirrhotic patients: 69% increase in bioavailability and increased half-life 1
- Patients with severely impaired renal function show similar pharmacokinetic profiles to those with normal function 1
Wide Inter-Patient Variability
Research demonstrates considerable variability among patients after single-dose administration 4. If a patient fails to respond adequately, plasma drug concentration determination can help assess whether adequate levels have been achieved 4.
Bottom Line for Clinical Practice
Diltiazem serum levels are measurable and correlate with clinical effect, but routine monitoring is not performed because:
- The therapeutic window is relatively wide
- Clinical endpoints (heart rate, blood pressure) are easily monitored
- Dose titration based on clinical response is standard practice 5, 6
The primary utility of knowing about diltiazem serum levels is understanding its pharmacokinetic behavior for drug interactions, dose adjustments in hepatic disease, and recognizing that higher doses produce disproportionately higher plasma concentrations due to non-linear kinetics.